Renzapride

  Renzapride is a full serotonin 5-HT₄ receptor agonist, partial serotonin 5-HT₃ receptor antagonist.

Product highlight

Precise electrochemical measurements in the smallest of spaces

Identify raw materials immediately - without waiting time

Precisely analyze halogens and sulphur in combustible materials

Clinical Uses

Renzapride is currently in Phase III clinical development in the United States for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). It is also potentially effective for irritable bowel syndrome with alternating stool pattern (IBS-A). It is being developed by Alizyme of the UK.